ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.3773
-0.0147 (-3.75%)
Mar 31, 2025, 3:35 PM EDT - Market open
ImmunoPrecise Antibodies Stock Forecast
IPA's stock price has decreased by -75.05% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ImmunoPrecise Antibodies stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 5.00. The average target predicts an increase of 960.16% from the current stock price of 0.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunoPrecise Antibodies stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +1,225.21% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,755.29% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | +1,755.29% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +2,285.37% | Sep 17, 2024 |
| Benchmark | Benchmark | Buy Maintains $5 → $3 | Buy | Maintains | $5 → $3 | +695.12% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
24.98M
from 24.52M
Increased by 1.88%
Revenue Next Year
27.45M
from 24.98M
Increased by 9.90%
EPS This Year
-0.39
from -1.06
EPS Next Year
-0.18
from -0.39
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 26.7M | 28.5M | 38.7M | |||
| Avg | 25.0M | 27.5M | 37.2M | |||
| Low | 23.5M | 26.6M | 36.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 9.0% | 14.3% | 40.8% | |||
| Avg | 1.9% | 9.9% | 35.5% | |||
| Low | -4.0% | 6.6% | 31.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.40 | -0.19 | 0.05 |
| Avg | -0.39 | -0.18 | 0.05 |
| Low | -0.39 | -0.18 | 0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.